The post Eli Lilly obesity pill orforglipron led to over 12% weight loss appeared on BitcoinEthereumNews.com.

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose more than 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial, paving way for its entrance into the market. Some doctors said the results appear to be comparable to, if not slightly lower, the level of weight loss seen with Novo Nordisk‘s blockbuster weekly GLP-1 injection for obesity, Wegovy. The data comes under what some Wall Street analysts were expecting for Eli Lilly’s oral GLP-1, with hopes for weight loss of around 15%. Some doctors also made note of the number of patients on the highest dose of the pill who discontinued treatment due to side effects or any other reason in the trial. Still, other doctors lauded the results and the potential of the pill to reach new patients, such as those who are afraid of needles.  “This is a strong and promising result for an oral agent,” said Dr. Jaime Almandoz, medical director of the Weight Wellness Program at UT Southwestern Medical Center, calling the weight loss “a significant and clinically meaningful outcome.” “Injectables have set a high bar, but this study reinforces the potential for an oral GLP-1 to be transformative in obesity care, particularly for patients who are hesitant to start or maintain injectable therapies,” he continued.  Dr. Mihail “Misha” Zilbermint, director of Endocrine Hospitalists at the Johns Hopkins Community Physicians, said he believes the pill “has the potential to be a game changer, as long as people can tolerate the side effects.” The trial results are among the pharmaceutical industry’s most closely watched studies of the year,…

---

Filed under: News - @ August 7, 2025 10:31 am